ArticlePloS one2023
Biogenic synthesis of ZnO and Al2O3 nanoparticles using Camellia sinensis and Origanum vulgare L. leaves extract for spectroscopic estimation of ofloxacin and ciprofloxacin in commercial formulations.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- Article
- Plant extract mediated synthesis of ZnO and CeOHeliyon · 2024Article
- Exploiting of Green Synthesized Metal Oxide Nanoparticles in the Potentiometric Determination of Metformin Hydrochloride in Pharmaceutical Products.International journal of analytical chemistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current study describes the biogenic synthesis of two metal oxides zinc oxide (ZnO), aluminum oxide (Al2O3) nanoparticles using Camellia sinensis, and Origanum vulgare L. leaves extract, respectively. The synthesized metal oxide nanoparticles were investigated using spectroscopic and microscopic techniques to confirm the formation of their nanostructures. Accurate and precise spectrofluorometric probes were proposed for the quantification of Ofloxacin (OFX) and Ciprofloxacin (CPFX) in their bulk and commercial formulations. The extraordinary properties of Zinc oxide and aluminum oxide nanoparticles (ZnONPs and Al2O3NPs) enhance the fluorescence intensity in the presence of 0.5 mL and 1.0 mL of sodium dodecyl sulfate (SDS, 1.0% w/v) as organizing agent for the detection of OFX and CPFX, respectively. The optical detection of both drugs at λex/em range 250-700 nm displayed linearity with a main correlation coefficient >0.999 at 1-300 (OFX-SDS-ZnONPs) and 0.5-100 (OFX-SDS-Al2O3NPs) ng mL-1,10-400 (CPFX-SDS-ZnONPs) and 0.1-50 (CPFX-SDS-Al2O3NPs) ng mL-1. The detection and quantification limits were found to be 0.04, 0.03, and 0.02, 0.04 ng mL-1, 0.13, 0.10, and 7.24, 0.09 ng mL-1 for the above-mentioned fluorescence systems, respectively. The suggested spectrofluorometric probes were validated and potentially applied for the estimation of OFX and CPFX in their bulk and commercial formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.